CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Targeting the epidermal growth factor receptor by erlotinib (Tarceva) for the treatment of esophageal cancer
DOI 10.1055/s-2005-920154
Bibliografische Angaben
Nachweis in CareLit
Autor:innenAP Sutter, M Höpfner, A Hüther, K Maaser, H Scherübl
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe04/2006
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background & Aims: Esophageal cancer is the sixth most common cause of cancer-related death worldwide. Due to very poor 5-year-survival new therapeutic approaches are mandatory. Erlotinib (TarcevaTM), an inhibitor of epidermal growth factor receptor tyrosine kinase (EGFR-TK), potently suppresses the growth of various tumors, but its effect on esophageal carcinoma, known to express EGFR, remains unexplored. We theref…
Zitieren
Zitierempfehlung
AP Sutter, M Höpfner, A Hüther, K Maaser, H Scherübl (2006) Targeting the epidermal growth factor receptor by erlotinib (Tarceva) for the treatment of esophageal cancer. Zeitschrift für Gastroenterologie (04). https://doi.org/10.1055/s-2005-920154
Mit CareLit weiterarbeiten